10-Q: Precision BioSciences Reports Strong Q2 Revenue Growth Driven by Collaboration Agreements

Precision BioSciences reports a significant increase in revenue for the second quarter of 2024, primarily driven by collaboration agreements and strategic transactions.

Summary

• Precision BioSciences reported a net income of $32.7 million for the three months ended June 30, 2024, and $41.3 million for the six months ended June 30, 2024, a significant turnaround from losses in the same periods of the previous year.
• The company's revenue for the second quarter of 2024 was $49.9 million, a substantial increase from $19.8 million in the same period of 2023, and $67.5 million for the six months ended June 30, 2024, compared to $28.6 million for the same period in 2023.
• This revenue growth was primarily driven by a $33.2 million increase related to the Prevail agreement, a $0.9 million increase from the TG License Agreement, and a $9.5 million increase from the TG License Agreement and the Caribou license agreement, partially offset by a $4.0 million decrease in revenue from the Novartis Agreement for the three months ended June 30, 2024, and a $5.3 million decrease for the six months ended June 30, 2024.
• Research and development expenses increased to $17.2 million for the three months ended June 30, 2024, and $30.6 million for the six months ended June 30, 2024, due to increased spending on the PBGENE-HBV and PBGENE-PMM programs.
• General and administrative expenses decreased to $8.5 million for the three months ended June 30, 2024, and $17.0 million for the six months ended June 30, 2024, due to reduced headcount and lower consulting fees.
• The company completed a 1-for-30 reverse stock split on February 13, 2024, and a public offering in March 2024, raising approximately $37.0 million in net proceeds.
• As of June 30, 2024, Precision BioSciences had cash and cash equivalents of $123.6 million and believes this, along with expected operational receipts, will fund operations into the second half of 2026.

Sentiment

Score: 7

Explanation: The document shows a positive financial turnaround with strong revenue growth and a clear strategic focus. However, the company still faces significant risks and uncertainties, which temper the overall sentiment.

Positives

• The company's revenue increased significantly due to collaboration agreements and strategic transactions.
• The company achieved a net income of $32.7 million for the three months ended June 30, 2024, and $41.3 million for the six months ended June 30, 2024, a substantial improvement from losses in the same periods of the previous year.
• The company has a strong cash position of $123.6 million as of June 30, 2024, which is expected to fund operations into the second half of 2026.
• The company is progressing its lead in vivo gene editing programs, PBGENE-HBV and PBGENE-PMM, with plans to submit IND or CTA applications.
• The company has secured a new term loan of $22.5 million with Banc of California, replacing the previous revolving line of credit.

Negatives

• Research and development expenses increased to $17.2 million for the three months ended June 30, 2024, and $30.6 million for the six months ended June 30, 2024, due to increased spending on the PBGENE-HBV and PBGENE-PMM programs.
• The company experienced a decrease in revenue from the Novartis Agreement, with a $4.0 million decrease for the three months ended June 30, 2024, and a $5.3 million decrease for the six months ended June 30, 2024.
• The company has a history of operating losses and may not achieve or maintain profitability.
• The company is dependent on the successful development and translation of its ARCUS technology, which is still in early stages of development.
• The company faces significant competition in the genome editing field, and competitors may develop superior products or treatments.

Risks

• The company's ability to become profitable is uncertain, and it may continue to incur losses for the foreseeable future.
• The company will need substantial additional funding, and if it is unable to raise sufficient capital, it may be forced to delay or reduce its research programs.
• The company has a limited operating history, which makes it difficult to evaluate its current business and future prospects.
• The company's ARCUS technology is novel, making it difficult to predict the time, cost, and potential success of product candidate development.
• The company faces significant competition in the genome editing field, and competitors may develop superior products or treatments.
• The company's product candidates may not work as intended or may cause undesirable side effects.
• The company's future success depends on its key executives and its ability to attract and retain qualified personnel.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in the delisting of its common stock.
• The company is subject to various legal and regulatory risks, including product liability lawsuits and compliance with healthcare laws.
• The company's reliance on third parties for manufacturing and clinical trials could lead to delays or difficulties.

Future Outlook

The company expects its existing cash and cash equivalents, along with expected operational receipts, to fund operations into the second half of 2026 and to achieve first-in-human Phase 1 clinical data for its lead in vivo gene editing programs. The company plans to submit an IND or CTA for PBGENE-HBV later this year and for PBGENE-PMM in 2025.

Management Comments

• The company is solely focused on leveraging its proprietary ARCUS genome editing platform to advance in vivo gene editing programs.
• The company's gene editing program PBGENE-HBV remains a top priority, and they expect to submit an IND application later this year.
• The company expects to submit an IND and/or CTA application in 2025 with respect to PBGENE-PMM.

Industry Context

This announcement reflects the ongoing development and commercialization efforts in the gene editing and biopharmaceutical industries, with a focus on in vivo therapies. The company's strategic shift towards complex gene edits and gene insertion aligns with the industry's move towards more sophisticated therapeutic approaches.

Comparison to Industry Standards

• The company's revenue growth is significant compared to many early-stage biotech companies, but it is important to note that this growth is largely driven by collaboration agreements and not product sales, which is typical for companies at this stage.
• The company's focus on in vivo gene editing is a competitive area, with companies like Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics also pursuing similar technologies, but with different approaches and targets.
• The company's cash runway into the second half of 2026 is relatively strong compared to many other companies in the sector, but it is important to note that this is based on current assumptions and may change.
• The company's progress with PBGENE-HBV and PBGENE-PMM is in line with the timelines of other companies developing gene editing therapies, but the success of these programs is still uncertain.
• The company's strategic divestment of its CAR T platform and focus on in vivo gene editing is a common strategy for companies in this sector, as it allows them to focus on their core competencies and reduce costs.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and the company's strategic focus.
• Employees may benefit from the company's growth and continued investment in research and development.
• Customers and partners may benefit from the company's progress in developing new therapies.
• Suppliers and creditors may benefit from the company's improved financial stability.

Next Steps

• The company plans to submit an IND or CTA for PBGENE-HBV later this year.
• The company expects to submit an IND and/or CTA application in 2025 with respect to PBGENE-PMM.
• The company will continue to evaluate returned programs from Prevail to determine the appropriate next steps.

Key Dates

Keywords

gene editing, ARCUS, in vivo therapy, PBGENE-HBV, PBGENE-PMM, clinical trials, biotechnology, collaboration agreements, financial results, regulatory approval